Not every type of immunotherapy works with every type of cancer.
Immunotherapy is a breakthrough cancer treatment that harnesses your own body’s immune system to identify and destroy cancer cells. When doctors talk about immunotherapy as a cancer treatment, they are actually referring to different kinds treatments that fall under the umbrella of immunotherapy, such as antibodies, vaccines, cytokines, and checkpoint inhibitors. Each immunotherapy treatment affects the immune system differently, and each immunotherapy option is FDA-approved to treat only certain kinds of cancer.
Antibodies have been successful for patients with breast cancer and non-hodgkin’s lymphoma. In this immunotherapy treatment, researchers create an antibody that specifically targets cancer-causing molecules in the body.
Another form of immunotherapy, vaccines are used to treat prostate cancer. These immunotherapy vaccines strengthen the body’s immune system so it is better able to respond to cancer.
Cytokines have been used to treat kidney cancer and melanoma. Cytokines are proteins produced by white blood cells, and they can aid in slowing the growth of cancer cells or even killing off cancer cells entirely. These are used less frequently since the emergence of checkpoint inhibitors, the newest class of immunotherapy treatment, which may work better for some patients.
Checkpoint inhibitors are FDA-approved to treat melanoma, non-small cell lung cancer, kidney cancer, bladder cancer, and non-hodgkin’s lymphoma. Checkpoint inhibitors help signal to the immune system which cells in the body to attack—and which to leave alone. This is important because cancer cells tend to find ways to evade the immune system, and checkpoint inhibitors counteract this.
Currently, researchers are testing whether immunotherapy can effectively treat even more types of cancer. Clinical trials for immunotherapy are being run for breast cancer, head and neck cancer, colorectal cancer, gastric cancer, and lymphomas.
Typically doctors use immunotherapy to treat metastatic cancer, which is when the cancer has already spread to other areas of the body. But doctors and researchers are researching how to use immunotherapy in earlier stages of cancer to help prevent cancer from returning in the first place.
Dr. Wilson is an assistant professor of medicine at NYU Langone’s Perlmutter Cancer Center, focusing on melanoma.
00:00:02,697 --> 00:00:05,162
Cancer immunotherapy is a global term, and
00:00:05,162 --> 00:00:09,740
it really encompasses very different
types of treatments for cancer patients.
00:00:09,740 --> 00:00:14,340
Some of these immunotherapies include
antibodies, some include vaccines,
00:00:14,340 --> 00:00:18,690
some include cytokines, and
some include checkpoint inhibitors.
00:00:18,690 --> 00:00:23,260
Using immunotherapy antibodies in
cancer has really revolutionized
00:00:23,260 --> 00:00:24,580
00:00:24,580 --> 00:00:29,060
In breast cancer, adding antibodies to
patients who express this one particular
00:00:29,060 --> 00:00:32,890
molecule has really improved outcomes for
00:00:32,890 --> 00:00:34,680
we see improved outcomes for
00:00:34,680 --> 00:00:38,450
patients with non-hodgkin's lymphoma
with the use of the antibody as well.
00:00:38,450 --> 00:00:44,740
Vaccines are proved to treat prostate
cancer, it's the sipuleucel-T vaccine.
00:00:44,740 --> 00:00:48,059
And cytokines have certainly been used
less since the advent of checkpoint
00:00:48,059 --> 00:00:48,697
00:00:48,697 --> 00:00:53,662
However, there still are certain times
where it is used, it is used with kidney
00:00:53,662 --> 00:00:58,047
cancer and it is actually used in
adopted T cell transfer in melanoma.
00:00:58,047 --> 00:01:02,960
So, checkpoint inhibitors are approved
to treat melanoma, non-small cell lung
00:01:02,960 --> 00:01:08,025
cancer, kidney cancer, bladder cancer,
and non-hodgkin's lymphoma.
00:01:08,025 --> 00:01:11,365
So, immunotherapy is actually being
explored to treat a number of other
00:01:11,365 --> 00:01:13,205
kinds of cancers in clinical trials.
00:01:13,205 --> 00:01:17,030
Including, breast cancer,
head and neck cancer,
00:01:17,030 --> 00:01:22,300
colorectal cancer, gastric cancer,
and other types of lymphomas as well.
00:01:22,300 --> 00:01:26,540
Right now, we're using immunotherapy
mainly, in metastatic disease.
00:01:26,540 --> 00:01:29,530
Meaning, what we're trying to prevent
cancer that's already spread.
00:01:29,530 --> 00:01:35,060
And, we're using what we've learned from
treatment now to make future decisions.
00:01:35,060 --> 00:01:38,430
And so right now, we're doing better at
treating patients once has disease has
00:01:38,430 --> 00:01:40,240
they develop metastatic disease.
00:01:40,240 --> 00:01:43,830
And we're seeing responses,
partial responses and complete responses.
00:01:43,830 --> 00:01:46,124
We're actually using this information and
00:01:46,124 --> 00:01:49,658
saying well can we now use these
medicines, use these antibodies,
00:01:49,658 --> 00:01:53,262
use these immunotherapies to prevent
the disease from coming back.
00:01:53,262 --> 00:01:57,365
And so I suspect we'll see more clinical
trials using these medicines in
00:01:57,365 --> 00:02:00,942
the adjuvant setting, again,
in earlier stages of cancers.
00:02:00,942 --> 00:02:03,121
To try to prevent the disease
from coming back, and
00:02:03,121 --> 00:02:05,662
it's very possible we'll see
these move into that realm.